Satellos Bioscience (TSE:MSCL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Satellos Bioscience has reported promising preliminary results for SAT-3247, a new treatment aimed at Duchenne muscular dystrophy (DMD). The treatment has shown to improve muscle repair and regeneration, as well as muscle force in a canine model of DMD, with plans to initiate Phase 1 clinical trials by the third quarter of 2024. This advancement could mark significant progress in the treatment of muscle diseases, as evidenced by a substantial increase in the Regenerative Index from the study.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
